Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
Berge E, Cohen G, Roaldsen MB, Lundström E, Isaksson E, Rudberg AS, Slot KB, Forbes J, Smith J, Drever J, Wardlaw JM, Lindley RI, Sandercock PA, Whiteley WN; IST-3 Collaborative Group.
Berge E, et al.
Lancet Neurol. 2016 Sep;15(10):1028-34. doi: 10.1016/S1474-4422(16)30139-9. Epub 2016 Jul 20.
Lancet Neurol. 2016.
PMID: 27450474
Clinical Trial.
METHODS: In IST-3, done at 156 hospitals in 12 countries (Australia, Europe, and the UK), participants (aged >18 years) were randomly assigned with a telephone voice-activated or web-based system in a 1:1 ratio to treatment with intravenous 0.9 mg/kg alteplase plus stan …
METHODS: In IST-3, done at 156 hospitals in 12 countries (Australia, Europe, and the UK), participants (aged >18 years) were randomly ass …